v3.26.1
Revenue - Implied Share of Net Sales (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Viatris | YUPELRI Monotherapy | Theravance Biopharma, Inc.        
Revenues:        
Revenues $ 24,733 $ 23,216 $ 46,584 $ 43,636